Nature Nano: Oral Nanomotors for Mitochondrial Transplantation

已传文件：photo/1768810516.png Recently, Mimi Wan et al. developed an oral nanomotor for achieving mitochondrial transplantation to treat ischemic heart disease.
Mitochondrial transplantation is an important therapeutic strategy for restoring energy supply in patients with ischemic heart disease (IHD), but it is limited by the invasiveness of the transplantation method and the loss of mitochondrial activity. Here, the authors report an oral administration treatment for IHD using mitochondrial transplantation. Specifically, the research team developed a new type of nanomotorized mitochondria, which can release nitric oxide and have the ability to target damaged cardiac tissue. At the same time, the nanized mitochondria are encapsulated in intestinal capsules to protect them from gastric acid erosion. After oral administration, the mitochondria are released into the intestine, where they are rapidly absorbed by intestinal cells and secreted into the blood and transported to the damaged cardiac tissue. The regulation of the disease microenvironment by the nanomotorized mitochondria enables rapid uptake and high retention of mitochondria by damaged myocardial cells and maintains the high activity of the transplanted mitochondria. This study demonstrates a non-invasive treatment strategy that changes the current methods for treating ischemic heart disease and is expected to provide a safer and more effective treatment option for patients.